• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.2260 +0.0060 (+2.73%)
Official Closing Price Updated: 6:30 PM EDT, Apr 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,895,622
Open 0.2239
Bid (Size) 0.2250 (200)
Ask (Size) 0.2268 (13,900)
Prev. Close 0.2200
Today's Range 0.2112 - 0.2292
52wk Range 0.2088 - 19.20
Shares Outstanding 7,167,721
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Early Trial Suggests mRNA Vaccine Could Be Effective Against Pancreatic Cancer
April 22, 2026
Via Investor Brand Network
News headline image
RedChip's Biotech Virtual Investor Conference Replays Now Available
April 21, 2026
Via ACCESS Newswire

Performance

YTD
-80.8%
-80.8%
1 Month
-20.6%
-20.6%
3 Month
-78.3%
-78.3%
6 Month
-85.1%
-85.1%
1 Year
-96.1%
-96.1%

More News

Read More
New AI Tool Could Boost the Early Detection of Lung Cancer
April 16, 2026
Via Investor Brand Network
Topics Artificial Intelligence
New Urine Test Boosts Forecasting of Treatment Outcomes in Bladder Cancer
April 13, 2026
Via Investor Brand Network
Immunotherapy Could Be Boosted by Blocking the Removal of Cancer RNA
April 10, 2026
Via Investor Brand Network
Scientists Discover Why Immunotherapy Frequently Fails
February 04, 2026
Via Investor Brand Network
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
April 07, 2026
Via ACCESS Newswire
Report Forecasts the Cancer Immunotherapy Market Hitting $311.4B by 2031
April 02, 2026
Via Investor Brand Network
Research Suggests the Thymus is Critical in Immunotherapy Outcomes
March 30, 2026
Via Investor Brand Network
Topics Artificial Intelligence
Major Discovery Could Reshape Cancer Immunotherapy
March 27, 2026
Via Investor Brand Network
Oncolytic Virus Therapy is Set to Transform Cancer Care
March 20, 2026
Via Investor Brand Network
Scientists Discover Why Colon Cancer Diagnoses are Increasing in Young Adults
March 18, 2026
Via Investor Brand Network
Microbial Ecosystems Play a Big Role in the Efficacy of Cancer Immunotherapy
March 13, 2026
Via Investor Brand Network
Unusual volume stocks in Tuesday's session ↗
March 10, 2026
Via Chartmill
Ongoing Digital Monitoring Could Make Immunotherapy More Accessible
March 09, 2026
Via Investor Brand Network
OSU Researchers Develop Nanomaterial That Eliminates Cancer Cells
March 06, 2026
Via Investor Brand Network
UCLA Researchers Develop Method to Fix Fuel Shortages in Cancer Immunotherapy
February 27, 2026
Via Investor Brand Network
Engineered Nanoparticles Hold Promise in Delivering Precision Cancer Treatments
February 25, 2026
Via Investor Brand Network
Cancer Stress Protein Enables Tumors to Evade the Immune System
February 20, 2026
Via Investor Brand Network
Existing Cancer Drug Shows Potential in Reactivating Immunotherapy
February 17, 2026
Via Investor Brand Network
Early Symptoms of Lung Cancer You Could Be Ignoring
February 12, 2026
Via Investor Brand Network
Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies
February 05, 2026
Via Investor Brand Network
Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds
January 29, 2026
Via Investor Brand Network
Novel Therapy Helps Tumor Cells Welcome Cancer Treatment
January 28, 2026
Via Investor Brand Network
Scientists Develop Next-Gen Antibodies That Boost the Body’s Cancer Killing Cells
January 21, 2026
Via Investor Brand Network

Frequently Asked Questions

Is Calidi Biotherapeutics, Inc. Common Stock publicly traded?
Yes, Calidi Biotherapeutics, Inc. Common Stock is publicly traded.
What exchange does Calidi Biotherapeutics, Inc. Common Stock trade on?
Calidi Biotherapeutics, Inc. Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Calidi Biotherapeutics, Inc. Common Stock?
The ticker symbol for Calidi Biotherapeutics, Inc. Common Stock is CLDI on the New York Stock Exchange
What is the current price of Calidi Biotherapeutics, Inc. Common Stock?
The current price of Calidi Biotherapeutics, Inc. Common Stock is 0.2260
When was Calidi Biotherapeutics, Inc. Common Stock last traded?
The last trade of Calidi Biotherapeutics, Inc. Common Stock was at 04/24/26 06:30 PM ET
What is the market capitalization of Calidi Biotherapeutics, Inc. Common Stock?
The market capitalization of Calidi Biotherapeutics, Inc. Common Stock is 1.62M
How many shares of Calidi Biotherapeutics, Inc. Common Stock are outstanding?
Calidi Biotherapeutics, Inc. Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap